keyword
MENU ▼
Read by QxMD icon Read
search

Bisphosphonates in prostate cancer

keyword
https://www.readbyqxmd.com/read/29370211/osteoclast-inhibitors-to-prevent-bone-metastases-in-men-with-high-risk-non-metastatic-prostate-cancer-a-systematic-review-and-meta-analysis
#1
Aimee R Hayes, Daniel Brungs, Nick Pavlakis
BACKGROUND: In advanced prostate cancer, osteoclast inhibitors prevent and palliate skeletal related events associated with bone metastases. However, it is uncertain whether they play a disease-modifying role earlier in the course of the disease. METHODS: Medline, EMBASE, Cochrane Central Register of Controlled Trials and Cochrane Database of Systematic Reviews and ASCO conference proceedings were searched for randomized controlled trials that compared osteoclast inhibitors with placebo and/or standard of care (SOC) in patients with high-risk, non-metastatic prostate cancer...
2018: PloS One
https://www.readbyqxmd.com/read/29300112/zoledronic-acid-overcomes-chemoresistance-by-sensitizing-cancer-stem-cells-to-apoptosis
#2
H Rouhrazi, N Turgan, G Oktem
Unlike low tumorigenic bulk tumor cells (non-CSCs), cancer stem cells (CSCs) are a subset of tumor cells that can self-renew and differentiate into different cancer subtypes. CSCs are considered responsible for tumor recurrence, distant metastasis, angiogenesis, and drug or radiation resistance. CSCs also are resistant to apoptosis. Zoledronic acid (ZA) is a third generation bisphosphonate that reduces cell proliferation and exhibits anti-tumor effects by inducing cell death in some malignancies; however, the effects of ZA on CSCs are unclear...
January 4, 2018: Biotechnic & Histochemistry: Official Publication of the Biological Stain Commission
https://www.readbyqxmd.com/read/29278410/bisphosphonates-for-advanced-prostate-cancer
#3
REVIEW
Sascha Macherey, Ina Monsef, Franziska Jahn, Karin Jordan, Kwok Keung Yuen, Axel Heidenreich, Nicole Skoetz
BACKGROUND: The prevalence and incidence of pain and skeletal complications of metastatic bone disease such as pathologic fractures, spinal cord compression and hypercalcemia is high and an important contributor to morbidity, poor performance status and decreased quality of life. Moreover, pathologic fractures are associated with increased risk of death in people with disseminated malignancies. Therefore, prevention of pain and fractures are important goals in men with prostate cancer at risk for skeletal complications...
December 26, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29224174/cost-effectiveness-of-treatments-for-the-management-of-bone-metastases-a-systematic-literature-review
#4
REVIEW
Lazaros Andronis, Ilias Goranitis, Sue Bayliss, Rui Duarte
BACKGROUND: Metastatic cancers occur when cancer cells break away from the primary tumour. One of the most common sites of metastasis is the bone, with several therapeutic options currently available for managing bone metastases. In a resource-constrained environment, policy makers and practitioners need to know which options are cost effective. OBJECTIVE: The aim of this systematic review was to review and appraise published economic evaluations on treatments for the management of bone metastases...
December 9, 2017: PharmacoEconomics
https://www.readbyqxmd.com/read/29211305/improving-bone-health-in-men-with-prostate-cancer-receiving-androgen-deprivation-therapy-results-of-a-randomized-phase-2-trial
#5
Shabbir M H Alibhai, Henriette Breunis, Narhari Timilshina, Maryam S Hamidi, Angela M Cheung, George A Tomlinson, Tharsika Manokumar, Osai Samadi, Joanna Sandoval, Sara Durbano, Padraig Warde, Jennifer M Jones
BACKGROUND: Strategies to improve bone health care in men receiving androgen deprivation therapy (ADT) are not consistently implemented. The authors conducted a phase 2 randomized controlled trial of 2 education-based models-of-care interventions to determine their feasibility and ability to improve bone health care. METHODS: A single-center parallel-group randomized controlled trial of men with prostate cancer who were receiving ADT was performed. Participants were randomized 1:1:1 to 1) a patient bone health pamphlet and brief recommendations for their family physician (BHP+FP); 2) a BHP and support from a bone health care coordinator (BHP+BHCC); or 3) usual care...
December 6, 2017: Cancer
https://www.readbyqxmd.com/read/29124881/the-implications-of-baseline-bone-health-assessment-at-initiation-of-androgen-deprivation-therapy-for-prostate-cancer
#6
Peter S Kirk, Tudor Borza, Vahakn B Shahinian, Megan E V Caram, Danil V Makarov, Jeremy B Shelton, John T Leppert, Ryan M Blake, Jennifer A Davis, Brent K Hollenbeck, Anne Sales, Ted A Skolarus
OBJECTIVES: To assess bone-density testing (BDT) use amongst prostate cancer survivors receiving androgen-deprivation therapy (ADT), and downstream implications for osteoporosis and fracture diagnoses, as well as pharmacological osteoporosis treatment in a national integrated delivery system. PATIENTS AND METHODS: We identified 17 017 men with prostate cancer who received any ADT between 2005 and 2014 using the Veterans Health Administration cancer registry and administrative data...
November 10, 2017: BJU International
https://www.readbyqxmd.com/read/29100167/early-identification-and-intervention-matters-a-comprehensive-review-of-current-evidence-and-recommendations-for-the-monitoring-of-bone-health-in-patients-with-cancer
#7
REVIEW
Thomas Brodowicz, Peyman Hadji, Daniela Niepel, Ingo Diel
Bone metastases are common in patients with advanced solid tumors, and many individuals experience debilitating skeletal-related events (SREs; e.g. pathologic fracture, hypercalcemia, radiotherapy or surgery to bone, and spinal cord compression). These events substantially affect disease outcomes, including survival and quality of life, and healthcare systems. Plain radiography is the most widely used imaging modality for the detection of bone metastases; skeletal scintigraphy, computed tomography, positron emission tomography and magnetic resonance imaging offer greater sensitivity but their use in routine practice is restricted by high costs and limited availability...
December 2017: Cancer Treatment Reviews
https://www.readbyqxmd.com/read/29052442/denosumab-for-the-treatment-of-bone-disease-in-solid-tumors-and-multiple-myeloma
#8
Andrew J Yee, Noopur S Raje
Bone is a common site for malignant involvement, either as a site of metastasis, especially in breast or prostate cancer, or as a defining characteristic of the disease, as in multiple myeloma. Bone disease is a major source of morbidity, and half of patients with bone involvement develop skeletal-related events such as pathological fractures or cord compression requiring surgery and/or radiation. Skeletal involvement also increases mortality, as pathologic fractures increase the risk of dying by 20-40%. Osteoclast inhibition with bisphosphonates such as zoledronic acid and recently denosumab has been a significant improvement for bone disease...
October 20, 2017: Future Oncology
https://www.readbyqxmd.com/read/28983908/interventions-for-managing-medication-related-osteonecrosis-of-the-jaw
#9
REVIEW
Natalie H Beth-Tasdogan, Benjamin Mayer, Heba Hussein, Oliver Zolk
BACKGROUND: Medication-related osteonecrosis of the jaw (MRONJ) is a severe adverse reaction experienced by some individuals to certain medicines commonly used in the treatment of cancer and osteoporosis (e.g. bisphosphonates, denosumab and antiangiogenic agents) and involves the progressive destruction of bone in the mandible or maxilla. Depending on the drug, its dosage, and the duration of exposure, the occurrence of this adverse drug reaction may be rare (e.g. following the oral administration of bisphosphonate or denosumab treatments for osteoporosis, or antiangiogenic agent-targeted cancer treatment) or common (e...
October 6, 2017: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/28921820/systematic-review-and-network-meta-analysis-on-the-relative-efficacy-of-osteoporotic-medications-men-with-prostate-cancer-on-continuous-androgen-deprivation-therapy-to-reduce-risk-of-fragility-fractures
#10
REVIEW
Yeesha Poon, Petros Pechlivanoglou, Shabbir M H Alibhai, David Naimark, Jeffrey S Hoch, Emmanuel Papadimitropoulos, Mary-Ellen Hogan, Murray Krahn
Androgen-deprivation therapy (ADT) is an effective treatment for men with advanced prostate cancer, but loss of bone mineral density (BMD) is a major risk factor for fractures. This review compared the efficacy of available treatments to provide prescribing guidance to healthcare professionals. This is the first review to compare the effectiveness of different osteoporotic treatments (bisphosphonates, denosumab, toremifene, and raloxifene) on BMD in patients with non-metastatic prostate cancer on ADT using network meta-analysis...
January 2018: BJU International
https://www.readbyqxmd.com/read/28914765/statin-and-bisphosphonate-induce-starvation-in-fast-growing-cancer-cell-lines
#11
Heidrun Karlic, Florian Haider, Roman Thaler, Silvia Spitzer, Klaus Klaushofer, Franz Varga
Statins and bisphosphonates are increasingly recognized as anti-cancer drugs, especially because of their cholesterol-lowering properties. However, these drugs act differently on various types of cancers. Thus, the aim of this study was to compare the effects of statins and bisphosphonates on the metabolism (NADP⁺/NADPH-relation) of highly proliferative tumor cell lines from different origins (PC-3 prostate carcinoma, MDA-MB-231 breast cancer, U-2 OS osteosarcoma) versus cells with a slower proliferation rate like MG-63 osteosarcoma cells...
September 15, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28862868/dna-polymerase-%C3%AE-cancer-associated-variant-i260m-exhibits-nonspecific-selectivity-toward-the-%C3%AE-%C3%AE-bridging-group-of-the-incoming-dntp
#12
Khadijeh S Alnajjar, Amirsoheil Negahbani, Maryam Nakhjiri, Ivan S Krylov, Boris A Kashemirov, Charles E McKenna, Myron F Goodman, Joann B Sweasy
The hydrophobic hinge region of DNA polymerase β (pol β) is located between the fingers and palm subdomains. The hydrophobicity of the hinge region is important for maintaining the geometry of the binding pocket and for the selectivity of the enzyme. Various cancer-associated pol β variants in the hinge region have reduced fidelity resulting from a decreased discrimination at the level of dNTP binding. Specifically, I260M, a prostate cancer-associated variant of pol β, has been shown to have a reduced discrimination during dNTP binding and also during nucleotidyl transfer...
October 10, 2017: Biochemistry
https://www.readbyqxmd.com/read/28805551/bone-targeted-cabazitaxel-nanoparticles-for-metastatic-prostate-cancer-skeletal-lesions-and-pain
#13
Andrew S Gdowski, Amalendu Ranjan, Marjana R Sarker, Jamboor K Vishwanatha
AIM: The aim of this study was to develop a novel cabazitaxel bone targeted nanoparticle (NP) system for improved drug delivery to the bone microenvironment. MATERIALS & METHODS: Nanoparticles were developed using poly(D,L-lactic-co-glycolic acid) and cabazitaxel as the core with amino-bisphosphonate surface conjugation. Optimization of nanoparticle physiochemical properties, in vitro evaluation in prostate cancer cell lines and in vivo testing in an intraosseous model of metastatic prostate cancer was performed...
September 2017: Nanomedicine
https://www.readbyqxmd.com/read/28717700/prostate-cancer-burden-at-the-uganda-cancer-institute
#14
Fred Okuku, Jackson Orem, George Holoya, Chris De Boer, Cheryl L Thompson, Matthew M Cooney
PURPOSE: In Uganda, the incidence of prostate cancer is increasing at a rate of 5.2% annually. Data describing presentation and outcomes for patients with prostate cancer are lacking. METHODS: A retrospective review of medical records for men with histologically confirmed prostate cancer at the Uganda Cancer Institute (UCI) from January 1 to December 17, 2012, was performed. RESULTS: Our sample included 182 men whose mean age was 69.5 years (standard deviation, 9...
August 2016: Journal of Global Oncology
https://www.readbyqxmd.com/read/28688625/bilateral-retrobulbar-optic-neuropathy-as-the-only-sign-of-zoledronic-acid-toxicity
#15
Félix Manco Lavado, Marta Para Prieto, María Rosalba Ramoa Osorio, María Isabel López Gálvez, Lucía Manzanas Leal
INTRODUCTION: Bisphosphonates may rarely cause ocular adverse effects and retrobulbar optic neuropathy (RON) secondary to zoledronic acid is very rare. CASE REPORT: A 67-year-old man was referred because of progressive and painless decrease vision in the left eye. He had been treated with 7 cycles of zoledronic acid infusions because of metastatic prostate cancer. On examination, VA was 20/20 in the right eye (OD) and 20/50 in the left eye (OS). The optic nerve was unremarkable OU...
October 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/28598810/the-prevention-of-fragility-fractures-in-patients-with-non-metastatic-prostate-cancer-a-position-statement-by-the-international-osteoporosis-foundation
#16
REVIEW
Luisella Cianferotti, Francesco Bertoldo, Marco Carini, John A Kanis, Alberto Lapini, Nicola Longo, Giuseppe Martorana, Vincenzo Mirone, Jean-Yves Reginster, Rene Rizzoli, Maria Luisa Brandi
Androgen deprivation therapy is commonly employed for the treatment of non-metastatic prostate cancer as primary or adjuvant treatment. The skeleton is greatly compromised in men with prostate cancer during androgen deprivation therapy because of the lack of androgens and estrogens, which are trophic factors for bone. Men receiving androgen deprivation therapy sustain variable degrees of bone loss with an increased risk of fragility fractures. Several bone antiresorptive agents have been tested in randomized controlled trials in these patients...
May 18, 2017: Oncotarget
https://www.readbyqxmd.com/read/28525684/223ra-dichloride-response-in-a-patient-with-paget-disease-and-bone-metastases-secondary-to-castration-resistant-prostate-cancer
#17
Lina García Cañamaque, Cristina Rioja Parada, Paloma García De la Peña
PURPOSE: Paget disease is commonly asymptomatic and discovered when an imaging test is performed for another clinical indication or when elevated serum alkaline phosphatase is found. Bone pain usually appears late in the disease process and is only present in a minority of patients. For diagnosis, X-ray and bone scan are the most recommended imaging methods; radionuclide imaging of the skeleton has become the standard, since it is the most sensitive test for detecting increased bone activity...
May 18, 2017: Tumori
https://www.readbyqxmd.com/read/28485692/cost-effectiveness-of-denosumab-versus-zoledronic-acid-for-preventing-skeletal-related-events-in-the-czech-republic
#18
Joaquim Cristino, Jíndřich Finek, Petra Jandova, Martin Kolek, Bálint Pásztor, Christina Giannopoulou, Yi Qian, Tomas Brezina, Mickael Lothgren
AIMS: This study assessed the cost-effectiveness of the subcutaneous RANKL inhibitor, denosumab, vs the intravenous bisphosphonate, zoledronic acid, for the prevention of skeletal-related events (SREs) in patients with prostate cancer, breast cancer, and other solid tumors (OST) in the Czech Republic. MATERIALS AND METHODS: A lifetime Markov model was developed to compare the effects of denosumab and zoledronic acid on costs (including drug costs and administration, patient management, SREs, and adverse events), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios from a national payer perspective...
June 7, 2017: Journal of Medical Economics
https://www.readbyqxmd.com/read/28381439/tumor-stroma-interactions-in-bone-metastasis-molecular-mechanisms-and-therapeutic-implications
#19
Hanqiu Zheng, Wenyang Li, Yibin Kang
Metastasis and associated complications are the major cause of death for cancer patients. The incidence of bone metastasis is among the highest in cancers arising from breast, prostate, and lung. Common skeletal-related events caused by bone metastasis include aberrant bone remodeling (osteolytic, osteoblastic, and mixed), bone pain, fracture, spinal cord compression, and life-threatening hypercalcemia. It is now known that interactions between tumor cells and bone stroma lie at the core of major steps of bone-metastasis progression...
April 5, 2017: Cold Spring Harbor Symposia on Quantitative Biology
https://www.readbyqxmd.com/read/28277852/the-treatment-patterns-of-castration-resistant-prostate-cancer-in-japan-including-symptomatic-skeletal-events-and-associated-treatment-and-healthcare-resource-use
#20
Hiroji Uemura, Marco DiBonaventura, Ed Wang, Dianne Athene Ledesma, Kristen Concialdi, Yasuko Aitoku
BACKGROUND: Real-world treatment patterns of bone metastatic castration-resistant prostate cancer (mCRPC) in Japan were examined, focusing on treatment patterns and resource use differences attributed to symptomatic skeletal events (SSEs). METHODS: Urologists (N = 176) provided retrospective chart data for patients with mCRPC (N = 445) via online surveys. Descriptive analyses and chi-square tests evaluated treatment patterns and their differences by SSE presence; generalized linear mixed models examined healthcare resource utilization differences as a function of SSEs...
October 2017: Expert Review of Pharmacoeconomics & Outcomes Research
keyword
keyword
63984
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"